Zegfrovy (Sunvozertinib)

Sunvozertinib is a medicine used to treat a type of lung cancer that has a change in the EGFR gene called an exon 20 insertion. It is taken as a pill by mouth. It works by blocking the faulty EGFR signal that makes the cancer cells grow.

Brand names:Zegfrovy
Medication

What people taking Zegfrovy (Sunvozertinib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Zegfrovy (Sunvozertinib) for Non-Small Cell Lung Cancer?

NameHow it went

About Zegfrovy (Sunvozertinib)

What It's For

Sunvozertinib, sold as Zegfrovy, is a targeted cancer pill for adults with non-small cell lung cancer (NSCLC), the most common type of lung cancer, when the tumor carries a specific genetic change in the EGFR (epidermal growth factor receptor) gene called an exon 20 insertion. It is used when the cancer is locally advanced or has spread (metastatic) and has grown during or after platinum-based chemotherapy, the standard chemotherapy given first for many lung cancers. A tumor test approved by the US Food and Drug Administration (FDA) confirms the mutation before treatment starts. The FDA granted it accelerated approval in 2025. That means approval was based on how often tumors shrank and how long that lasted, and the company must still confirm in further trials that it helps people live longer or better. Another option for the same situation is amivantamab (Rybrevant), an antibody given by infusion that also targets EGFR, so the choice between them depends on prior treatment, practical preferences and side effects.

How It Works

EGFR is a protein on the surface of cells that, when switched on, signals the cell to grow and divide. In some lung cancers, a change in the EGFR gene leaves this signal stuck in the on position, driving the tumor's growth. Exon 20 insertions are one type of change: a small extra piece is inserted into the part of the protein that sends the signal. Sunvozertinib is a kinase inhibitor, a drug that blocks the signaling part of a protein like EGFR. It binds to EGFR proteins that carry exon 20 insertions and blocks their signal. Shutting down that growth signal can make tumors shrink or stop growing. It does not cure the cancer, and tumors often find ways to grow again over time.

Dosage & Administration

Zegfrovy comes as a tablet taken by mouth once a day, at about the same time each day, with food. Taking it with food helps reduce nausea and diarrhea. Swallow the tablets whole; do not split, crush, chew or dissolve them. If a dose is missed and fewer than 12 hours have passed, take it. If more than 12 hours have passed, skip it and take the next dose at the usual time. If you vomit after a dose, do not take another one; wait for the next scheduled dose. Treatment continues as long as it is working and side effects are manageable. Pauses and dose reductions are common: the oncologist may lower the dose to manage side effects, and some interacting medicines also require a dose change. Follow the dose on your current prescription rather than adjusting it yourself.

Side Effects

Diarrhea is the most common side effect, affecting about three in four people in studies, and nausea and vomiting affected more than four in ten. Skin problems are also very common: rash or acne-like spots, itching, dry skin and painful infection around the fingernails or toenails (paronychia). Other frequent effects include mouth sores, lower appetite, weight loss, tiredness, constipation, muscle or joint pain and urinary tract infections. Most are manageable with anti-diarrhea medicine, anti-nausea medicine, skin care or a dose change, but contact the care team right away if diarrhea, vomiting or rash starts, rather than waiting until it becomes severe. For the skin, the label advises using an alcohol-free moisturizing cream throughout treatment and avoiding irritating products such as retinol or retinoic acid creams and benzoyl peroxide acne treatments. Uncommonly, sunvozertinib causes serious inflammation of the lungs (pneumonitis or interstitial lung disease), which can be life-threatening. In studies it typically appeared within the first few months. Contact the care team immediately about new or worsening shortness of breath, cough or fever, since these can also be caused by the cancer or an infection and need to be sorted out quickly. Eye problems such as dryness, blurred vision or inflammation of the cornea (keratitis) also occur; report new or worsening eye symptoms, and stop wearing contact lenses until an eye specialist has checked them.

Interactions & Warnings

Sunvozertinib can harm a developing baby. People who could become pregnant should use effective non-hormonal birth control during treatment and for 2 weeks after the last dose, because sunvozertinib can make some hormonal birth control unreliable. Men with partners who could become pregnant should also use effective contraception for the same period. Tell the oncologist right away about a known or suspected pregnancy. Breastfeeding is not recommended during treatment or for 2 weeks after the last dose, and the drug may reduce fertility in both women and men. The liver breaks down sunvozertinib using an enzyme called CYP3A. Some medicines and supplements slow this enzyme and raise drug levels, increasing side effects, while others speed it up and can make the treatment less effective. Some of these combinations should be avoided, and others require a dose change. Sunvozertinib can also raise levels of certain other medicines. Before starting any new prescription, over-the-counter medicine, vitamin or herbal product, check with the oncologist or pharmacist.

What to Expect

Before starting, the tumor is tested to confirm the exon 20 insertion. In the main study, about 46% of people who had already received chemotherapy saw their tumors shrink substantially, including a small number whose visible cancer disappeared on scans. Among those who responded, the response lasted about 11 months on average, and nearly three in four kept their response for at least 6 months. Others had no meaningful shrinkage. Because the study had no comparison group, it is not yet known how much sunvozertinib extends survival. Scans are repeated at intervals to see whether the cancer is responding, and visits and blood tests track side effects. About half of people in studies needed at least one pause in treatment and about a quarter needed a lower dose, which is a normal part of keeping treatment tolerable rather than a sign it is failing. If the cancer grows despite treatment, the oncologist will discuss other options, including clinical trials.

Questions to Ask Your Doctor

  1. 1.How was the exon 20 insertion confirmed in my tumor, and is sunvozertinib or amivantamab the better fit for me?
  2. 2.What results are realistic for me, and how often will scans check whether it is working?
  3. 3.What should I keep on hand for diarrhea, nausea and skin care, and at what point should I call you?
  4. 4.Do any of my current medicines or supplements interact with sunvozertinib, and which non-hormonal birth control is right for me?
  5. 5.What would the next options be if this treatment stops working?

Last reviewed • Oct 2026

Educational content, not medical advice.